Christian Heichinger

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal: Journal for immunotherapy of cancer

Published: May 19, 2026

A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 09, 2026

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Journal: Journal for immunotherapy of cancer

Published: February 02, 2026

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Journal: Nature medicine

Published: January 17, 2026

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 21, 2025

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

Journal: Neuro-oncology advances

Published: August 22, 2025

Mapping MAGE-A4 expression in solid cancers for targeted therapies.

Mapping MAGE-A4 expression in solid cancers for targeted therapies.

Journal: Frontiers in oncology

Published: August 21, 2024

Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.

Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.

Journal: ACS chemical biology

Published: September 26, 2019

Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.

Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.

Journal: PloS one

Published: March 20, 2019

Contribution of epigenetic variation to adaptation in Arabidopsis.

Contribution of epigenetic variation to adaptation in Arabidopsis.

Journal: Nature communications

Published: December 08, 2017

Natural enemies drive geographic variation in plant defenses.

Natural enemies drive geographic variation in plant defenses.

Journal: Science (New York, N.Y.)

Published: October 09, 2012

The Polycomb group protein MEDEA and the DNA methyltransferase MET1 interact to repress autonomous endosperm development in Arabidopsis.

The Polycomb group protein MEDEA and the DNA methyltransferase MET1 interact to repress autonomous endosperm development in Arabidopsis.

Journal: The Plant journal : for cell and molecular biology

Published: August 08, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026